Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: Results of clinical trials

Neurology

Volumn 55, Issue 11 SUPPL. 4, 2000, Pages

  Kieburtz, K ^a   Hubble, J ^a   Olanow, ^a   Hubble, ^a   Dingemanse, ^a   Obeso, ^a   Stocchi, ^a   Rascol, ^a   Ventura, ^a   Koller, ^a   Schapira, ^a   LeWi tt, ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; LIVER FUNCTION; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; VOMITING;

BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSONIAN DISORDERS;

EID: 0034642346     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa-related fluctuations
2. Effect of peripheral catechol-O-methyl transferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
3. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
4. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
5. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
6. Entacapone enhances the responses to levodopa in parkinsonian patients with motor fluctuation
7. Tolcapone improves motor function in Parkinsonian patients with the 'wearing off' phenomenon: A double-blind, placebo-controlled, multicenter trial
8. Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients